Publications by authors named "Amir Karimzadeh"

Claim this Profile
I
Impact of baseline F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving Lu-PSMA-targeted radioligand therapy.
Amir Karimzadeh, Kimberley Hansen, Stefan Hein, Bernhard Haller, Matthias M Heck

Eur J Nucl Med Mol Imaging· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-Related Outcomes of [Lu]Lu-PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis.
Nikolaus Schweigert, Nadja Strewinsky, Daniel Köhler, Wencke Lehnert, Jonas Ekrutt, Amir Karimzadeh

Cancers (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Amir Karimzadeh, Wencke Lehnert, Daniel Koehler, Farzad Shenas, Anna Kisters

Rofo· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of the Cingulate Island Sign by Early Perfusion Imaging in Dopamine Transporter SPECT With Multiple-Pinhole Collimators.
Amir Karimzadeh, Anne Burkhardt, Susanne Klutmann, Ivayla Apostolova, Ralph Buchert

Clin Nucl Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Amir Karimzadeh, Wencke Lehnert, Daniel Koehler, Farzad Shenas, Anna Kisters

Nuklearmedizin· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic F-flotufolastat PET parameters for outcome assessment of Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer.
Amir Karimzadeh, Kimberley Hansen, Ergela Hasa, Bernhard Haller, Matthias M Heck

Eur J Nucl Med Mol Imaging· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion.
Ivayla Apostolova, Sabine Hellwig, Amir Karimzadeh, Susanne Klutmann, Philipp T Meyer

Eur J Nucl Med Mol Imaging· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matched-pair analysis of mCRPC patients receiving Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval.
Amir Karimzadeh, Charlotte-Sophie Hecker, Matthias M Heck, Robert Tauber, Calogero D'Alessandria

EJNMMI Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[False positive multifocal PSMA PET/CT in a patient with prostate cancer and B cell chronic lymphocytic leukemia].
Amir Karimzadeh, Katharina Möller, Thomas Steuber

Rofo· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain perfusion SPECT in the presurgical evaluation of epilepsy: is additional ictal SPECT required in case of high-confidence lateralization of the seizure onset zone by interictal SPECT and vice versa?
Kian Baradaran-Salimi, Amir Karimzadeh, Berthold Voges, Ivayla Apostolova, Thomas Sauvigny

EJNMMI Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organ and tumor dosimetry including method simplification for [Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer.
Amir Karimzadeh, Linus Schatz, Markus Sauer, Ivayla Apostolova, Ralph Buchert

EJNMMI Phys· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short post-injection seizure duration is associated with reduced power of ictal brain perfusion SPECT to lateralize the seizure onset zone.
Amir Karimzadeh, Kian Baradaran-Salimi, Berthold Voges, Ivayla Apostolova, Thomas Sauvigny

EJNMMI Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators.
Ralph Buchert, Balazs Szabo, Akos Kovacs, Thomas Buddenkotte, Franziska Mathies, Amir Karimzadeh

J Nucl Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments.
Inka Ristow, Lennart Well, Nis Jesper Wiese, Malte Warncke, Joseph Tintelnot, Amir Karimzadeh

Cancers (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific membrane antigen radioguided surgery with negative histopathology: an in-depth analysis.
Daniel Koehler, Samuel Trappe, Farzad Shenas, Amir Karimzadeh, Ivayla Apostolova

Eur J Nucl Med Mol Imaging· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PSMA hybrid imaging in prostate cancer - current applications and perspectives.
Daniel Koehler, Christoph Berliner, Farzad Shenas, Amir Karimzadeh, Ivayla Apostolova

Rofo· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of Lu-PSMA I&T.
Amir Karimzadeh, Paula Soeiro, Benedikt Feuerecker, Charlotte-Sophie Hecker, Karina Knorr

J Nucl Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
Amir Karimzadeh, Matthias Heck, Robert Tauber, Esteban Solaris, Stephan Nekolla

J Nucl Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
Lukas Lunger, Maythinee Chantadisai, Amir Karimzadeh, Isabel Rauscher, Calogero D'Alessandria

J Nucl Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers.
Amir Karimzadeh, Matthias Heck, Robert Tauber, Karina Knorr, Bernhard Haller

J Nucl Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of [ Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria.
Daniel Koehler, Markus Sauer, Amir Karimzadeh, Ivayla Apostolova, Susanne Klutmann

EJNMMI Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection efficacy of F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
Isabel Rauscher, Amir Karimzadeh, Kilian Schiller, Thomas Horn, Calogero D'Alessandria

J Nucl Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis